A study to compare the addition of Blinatumomab in combination with chemotherapy in patients diagnosed with standard risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B-ALL and the treatment of patients with localized B-cell Lymphoblastic Lymphoma (B-LLy)

The overall goal of Part I of this study is to collect information about your leukemia and your response to the first phase of treatment, called Induction. You may be offered the chance to take part in Part II of this study after Induction once your B-ALL risk group is known. Depending on your risk group, there is a chance that you may be randomized to receive the investigational medicine, blinatumomab plus standard treatment during Part II.